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Abstract
Background: FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated protein in a variety of human acute
leukemias. Mutations leading to constitutively active FLT3, including internal tandem duplications of the
juxtamembrane domain (ITD), result in continuous cellular proliferation, resistance to apoptotic cell death, and a
poorer prognosis. A better understanding of the molecular consequences of FLT3 activation would allow improved
therapeutic strategies in these patients. Canine lymphoproliferative diseases, including lymphoma and acute
leukemias, share evolutionarily conserved chromosomal aberrations and exhibit conserved mutations within key
oncogenes when compared to their human counterparts. A small percentage of canine acute lymphocytic
leukemias (ALL) also exhibit FLT3 ITD mutations.
Methods: We molecularly characterized FLT3 mutations in two dogs and one cell line, by DNA sequencing, gene
expression analysis via quantitative real-time PCR, and sensitivity to the FLT3 inhibitor lestaurtinib via in vitro
proliferation assays. FLT 3 and downstream mediators of FLT3 activation were assessed by Western blotting.
Results: The canine B-cell leukemia cell line, GL-1, and neoplastic cells from 2/7 dogs diagnosed cytologically with
ALL were found to have FLT3 ITD mutations and FLT3 mRNA up-regulation. Lestaurtinib, a small molecule FLT3
inhibitor, significantly inhibited the growth of GL-1 cells, while not affecting the growth of two other canine
lymphoid cell lines without the FLT3 mutation. Finally, western blots were used to confirm the conserved
downstream mediators of FLT3 activating mutations.
Conclusions: These results show that ALL and FLT3 biology is conserved between canine and human patients,
supporting the notion that canine ALL, in conjunction with the GL-1 cell line, will be useful in the development of
a relevant large animal model to aid in the study of human FLT3 mutant leukemias.
Background
FMS-like tyrosine kinase 3 (FLT3), one of the most
commonly mutated genes in human leukemias, is a class
III receptor tyrosine kinase that is an important regula-
tory gene involved in normal hematopoiesis [1,2]. FLT3
is expressed predominantly on myeloid and lymphoid
hematopoietic progenitors, where the receptor, once
bound by its cognate ligand (FLT3 ligand, FL), activates
a variety of downstream targets. These include proteins
in the signal transducers and activators of transcription
(STAT), mitogen-activated protein (MAP) kinase, and
AKT pathways that are all involved in regulating prolif-
eration, differentiation, and cell survival [1,2]. In vitro
studies have shown that constitutively activated FLT3
triggers downstream signaling pathways resulting in
continuous cellular proliferation and resistance to apop-
totic cell death. Constitutively activated FLT3 occurs via
two main mechanisms: coexpression of FL, which leads
to activation via autocrine, paracrine, or intracrine sig-
naling, or via mutation of the FLT3 gene itself, confer-
ring ligand independence [3-7]. Such mutations are
internal tandem duplications of the juxtamembrane
domain (ITD), point mutations of the juxtamembrane
domain, or point mutations of the second tyrosine
kinase domain (TKD). In transgenic murine model sys-
tems, constitutively activated FLT3 contributes to the
leukemic phenotype [1,2,8,9].
The majority of human acute leukemias, including
100% of B-cell lineage acute lymphoblastic leukemias
(ALL), 27% of T-lineage ALL, and 89% of acute
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myelogenous leukemias (AML) overexpress FLT3
[10,11]. ITD mutations are found in 3% of patients with
myelodysplastic syndromes (MDS) [1,12], and up to 15%
and 25% of pediatric and adult AML patients, respec-
tively [1,2,13-15]. In both pediatric and adult AML
patients, the presence of an ITD mutation is associated
with a significantly higher relapse rate and worse overall
survival [13-15]. FLT3 ITD mutations rarely occur in
adult acute lymphoblastic leukemias (ALL) of B-cell ori-
gin and childhood ALL [1,2]. Interestingly, some of the
highest levels of FLT3 expression occur in infant and
childhood ALL, therefore, a mechanism other than
mutation constitutively activates FLT3 in these cases
[16]. As a therapeutic target, FLT3 is appealing since it
is up-regulated in a significant number of acute leuke-
mias and its protein expression is restricted to primitive
and immature hematopoietic progenitors. Modest
results from clinical trials with a variety of small-
molecule FLT3 inhibitors suggest that improved
understanding of FLT3 mutations and the resultant
aberrations in signaling may be needed before we realize
the full therapeutic potential of these agents.
The domestic dog (Canis familiaris) is a useful large-
animal model of naturally occurring cancers, including
hematologic malignancies such as lymphomas and leu-
kemias. Canine hematologic malignancies share exten-
sive similarities with their human counterparts with
regards to clinical presentation, tumor biology and
response to therapy [17,18] and, in addition, human and
canine hematologic malignancies share evolutionarily
conserved chromosomal aberrations as well as conserved
mutations within key oncogenes [19,20]. Therefore,
canine hematologic malignancies are recognized as
appropriate models of their human counterparts [17],
and comparative studies between human and canine
patients may reveal common mechanisms of oncogen-
esis relevant to both species [21].
Recently, FLT3 mutations were reported in 4/57 (7%)
of dogs with cytologically and immunophenotypically
confirmed ALL [19], suggesting that this important
mechanism of leukemia development and/or progression
might be another instance of cross-species conservation
of pathogenic mechanism. Three dogs with B-cell ALL
harbored FLT3 ITD mutations of exons 14/15, while
one dog with ALL of an unknown phenotype had a
TKD-PM in exon 20. The functional consequences of
the identified mutations (i.e. FLT3 up-regulation) were
not examined.
Another suggestion of cross-species conservation of
FLT3 activation came from our efforts to further
characterize five previously reported malignant canine
lymphoid cell lines- GL-1, CL-1, 17-71, CLGL-90, and
CLL-1390 (manuscript submitted, Seiser EL, Thomas R,
Richards KL, Byler KK, Breen T, Moore P, Suter SE,
Breen M. Reading Between the Lines: Genomic Charac-
terization of Five Widely Utilized Canine Lymphoid
Tumor Cell Lines). Using array comparative genomic
hybridization (aCGH) analysis, we found that GL-1 [22],
a B-cell leukemia cell line, has an extensive copy num-
ber increase of the proximal half of dog chromosome
25, which harbors the FLT3 locus. Subsequent FISH
analysis using a BAC clone containing the entire FLT3
sequence, showed a copy number increase to 4N on
chromosome 25. These initial data suggested that the
GL-1 cell line could be a relevant in vitro model for
FLT3 activation, and if so, that canine leukemia models
could be of use in the development of targeted FLT3
inhibitors.
The aim of this study was to determine if the canine
GL-1 cell line and samples obtained from dogs diag-
nosed with ALL contain FLT3 mutations, to compare
any identified mutations to those previously reported in
both canine and human leukemia patients, and to deter-
mine whether the functional consequences of FLT3
mutation are conserved between dogs and humans.
Methods
Cell lines
The canine lymphoid cell lines, GL-1 (B-cell leukemia)
[22], 17-71 (B-cell lymphoma) [23], and CLGL-90
(chronic large granular T cell leukemia, kind gift from
Dr. Maxie Wellman, Ohio State University) [24], and
human cell line, MV4-11 (biphenotypic myelomonocytic
cell line) [25], were maintained in RPMI 1640 culture
medium (Mediatech, Inc., Hendon, VA) supplemented
with 10% fetal bovine serum (FBS, Mediatech, Inc),
2 mM L-glutamine (Mediatech, Inc) and 100 mg/ml Pri-
mocin (Invivogen, San Diego, CA) at 38°C/5% CO2. All
cell lines tested negative for mycoplasma infection using
a PCR-based test kit (AppliChem, Cheshire, CT). The
GL-1 and CLGL-90 cell lines exhibit near normal ploidy
(2n=78 for the domestic dog), with a range of 75-77
chromosomes and 77-82 chromosomes, respectively. The
17-71 cell line is hyperploid, with a range of 102-108
chromosomes. These cell lines were verified to match
available published karyotypic and immunophenotyping
information (manuscript submitted, Seiser EL, et al.).
Sample recruitment
Three ml ethylenediaminetetraacetic acid (EDTA) blood
samples were obtained during routine staging after
owner consent via venipuncture from seven dogs
presenting to the North Carolina State College of Veter-
inary Medicine Veterinary Teaching Hospital (NCSU-
VTH) with clinical signs and hematologic abnormalities
consistent with acute lymphoblastic leukemia. The study
protocol was approved by the Institutional Animal Care
and Use Committee of North Carolina State University.
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Blood smears stained with May Grunwald Giemsa were
examined by a board-certified veterinary clinical pathol-
ogist. Morphological evaluation included a 200-cell dif-
ferential white blood cell count. Flow cytometry was
performed (Clinical Immunology Service, NCSU-VTH)
using a panel of antibodies against CD3, CD4, CD8,
CD21, CD45, CD34, CD14, and CD79a. A diagnosis of
ALL was made based on a combination of morphologi-
cal evaluation of blood and/or bone marrow smears,
immunophenotyping, and hemogram analysis. These cri-
teria included > 30% blasts in the peripheral blood or
bone marrow, concurrent cytopenias, negative staining
of the neoplastic cells using a myeloid marker (CD14),
and positive staining using CD34, CD79a, CD21 (B-cell
ALL), or CD34, CD3, CD4, and CD8 (T-cell ALL). ALL
was differentiated from chronic lymphoid leukemia
(CLL) and the leukemic phase of lymphoma on the
basis of cell morphology, CD34 expression, and the dis-
tribution of organ involvement.
The canine ALL patients included two 8-year old and
one 9-year old male castrated Labrador Retrievers, one
6-year old female spayed Schipperke, one 10-year old
male castrated Border Collie, one 10.5-year old female
spayed Doberman Pinscher, and one 8-year old male
castrated mixed-breed dog. The ALL phenotypes were:
three B-cell ALL, three ALL of unknown phenotype,
and one dual-positive (i.e. T and B-cell markers) ALL.
Five of these patients had ≥ 100,000/ml leukemic blasts
in the peripheral blood (including both dogs harboring
the FLT3 ITD), while three patients had < 30,000/ml
leukemic blasts.
Polymerase chain reaction (PCR)
Genomic DNA was prepared from whole blood col-
lected by venipuncture from dogs diagnosed cytologi-
cally with ALL or from aliquots of cultured cell lines
using the ZR Genomic DNA II kit (Zymo Research,
Orange, CA) according to manufacturer instructions.
PCR was conducted in 50 ul reactions containing 1 ul of
genomic DNA (~35 ng); 25 ul Taq PCR MasterMix
(Qiagen Inc., Valencia, CA), and 400 nM each of for-
ward and reverse primers designed within intronic
regions of the FLT3 gene and prepared by the Nucleic
Acids Core Facility (University of North Carolina, Cha-
pel Hill, NC). The FLT3 14/15 intronic primer pairs, 5’-
CCA TTT CTG AGG GAC TGC-3’ and 5’-GCC TTG
AAA CAT GGC AAG C-3’, were used for amplification
of the exon regions 14 through 15 corresponding to the
juxtamembrane domain [19]. The FLT3 20 intronic pri-
mer pairs, 5’-TCA CCT GGA ATT CCT ACT GAA C-
3’ and 5’-TGT ACT ACA GCG GTT GTG GAC-3’
were used for amplification of exon 20 corresponding to
the tyrosine kinase domain [19]. PCR reaction condi-
tions were: 95°C for 3 min; followed by 37 cycles of
94°C for 30 s; 52°C (FLT3 14/15) or 55°C (FLT3 20) for
30 s; and 72°C for 1 min with a final elongation step of
72°C for 10 min. PCR amplicons were separated through
a 1.5% agarose gel, followed by ethidium bromide stain-
ing and visualization under ultraviolet light. DNA was
extracted from bands excised from the gel using a QIA-
quick Gel Extraction kit (Qiagen). Purified DNA was
then sequenced using the previously mentioned PCR
primers (Genomic Analysis Core Facility, University of
North Carolina, Chapel Hill, NC).
RNA preparation and quantitative real-time PCR
Peripheral blood mononuclear cells from a normal dog
were isolated as previously described [26], then frozen
in Trizol (Invitrogen, Carlsbad, CA) until RNA extrac-
tion per manufacturer’s instructions. ALL case 1 had an
excisional lymph node biopsy that was immediately
stored in Trizol at -80°C until extraction. Cell line pel-
lets were resuspended and frozen in Trizol at -80°C
until extraction. RNA from other ALL cases was
obtained from 200 ul of peripheral blood added to 1 ml
RNAlater (Qiagen), then frozen at -20°C until Trizol
extraction.
Total RNA from each sample was used to generate
cDNA for downstream analysis (Quantitect Reverse
Transcription Kit, Qiagen). Quantitative real-time PCR
(qRT-PCR) was performed using the Quantitect SYBR
Green Kit (Qiagen) and an iCycler (BioRad, Hercules,
CA). The gene RPL32 was selected as the reference for
quantitative analysis based on its stable expression across
all samples examined by gene expression microarray (see
below); PCR primers (forward: 5’-ATG CCC AAC ATT
GGT TAT GG-3’, reverse: 5’-CTC TTT CCA CGA TGG
CTT TG-3’) were designed as described previously [27].
FLT3 primers (Entrez GeneID: 486025, forward: 5’-CAG
AGG CAG TGT ATG GAG CA-3’, reverse: 5’-GGC
AAT TCA GGG AAC TGT GT-3’) were designed using
NCBI Primer-BLAST (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). The reaction efficiency for the primer sets used was
calculated using serial dilutions of cDNA, with efficien-
cies ranging from 90%-100%. Relative quantification was
performed as described previously [28]. All qRT-PCR
assays were performed in triplicate.
Proliferation assays
Cells were seeded at 4 × 104 cells in a 96-well plate in a
total volume of 200 ul and treated with 5 or 10 nM les-
taurtinib for 96 hours. Proliferation was measured using
Alamar Blue (AbD Serotec Ltd, Oxford, UK) according
to manufacturer instructions. Fluorescence was mea-
sured using a DTX880 Multimode Detector (Beckman
Coulter, Brea, CA) with excitation at 535 nm and emis-
sion at 595 nm. All assays were performed in triplicate
and growth experiments were each repeated three times;
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standard error of the mean was calculated for the
averages. Proliferation was expressed relative to
untreated controls.
Western blotting
Cells were seeded at 2 × 106 cells in 2 ml of RPMI sup-
plemented with penicillin G sodium (100 U/ml), strepto-
mycin sulfate (100 ug/ml), and 0.5% bovine serum
albumin under serum-free conditions for 24 hours and
then treated for 2 hours with or without 10 nM lestaurti-
nib (LC Laboratories, Woburn, MA). Cells were then
lysed in RIPA buffer (Dulbecco’s PBS, 0.1% Sodium
Dodecyl Sulfate, 0.5% Sodium Deoxycholate, and 1% Ipe-
gal NP-40 supplemented with 1 mM PMSF (phenyl-
methylsulfonylfluoride), 1x complete protease inhibitor
cocktail (Roche Diagnostics, Indianapolis, IN), and 1x
Phosphatase Inhibitor Cocktail 2 (Sigma, St. Louis, MO)).
An aliquot was used for protein quantification using the
BCA protein assay kit (Pierce Technology, Inc., St. Louis,
MO). The remaining sample was mixed with 0.5 volumes
of 3x SDS sample buffer (1x equals 31.25 mM Tris-HCl
(pH 6.8), 2% SDS, 5% 2-mercaptoethanol, 10% sucrose,
and 0.005% bromophenol blue). Equivalent protein
amounts were run on SDS-PAGE in Tris/glycine/SDS
buffer using 10% acrylamide gels. Resolved proteins were
then transferred to a PVDF (polyvinylidene difluoride)
membrane Antibodies directed against FLT3, phospho-
FLT3, phospho-MAPK (Thr202/Tyr204) and phospho-
Stat5 (Tyr694) (Cell Signaling, Boston, MA) were used.
Anti-beta-actin (Sigma) was used as a loading control.
Horseradish peroxidase-conjugated secondary antibodies
were used with an ECL or ECL Plus detection reagent
(GE Healthcare Bio-Sciences Corp., Piscataway, NJ) to
visualize immunoreactive bands.
Results
Identification of FLT3 ITD mutations in a canine ALL cell
line and in canine leukemia patient samples
We first evaluated the canine lymphoid cell lines for the
presence of either exon 14/15 ITDs or exon 20 TKD
point mutations using genomic PCR. Using previously
published primers, the wild-type exon 14/15 product
seen in the 17-71 and CLGL-90 cell lines is 500 bp
(Figure 1, lanes 3, 4). In contrast, the GL-1 leukemia
cell line yielded only a ~525 bp amplicon (Figure 1 lane
7), suggesting the possibility of an ITD and indicative of
a complete loss of the wild-type FLT3 sequence. GL-1
cells, therefore, reveal loss of heterozygosity in the area
of chromosome 25 containing the FLT3 gene (25 q
LOH). No point mutations were identified by DNA
sequencing of both exon 14/15 and exon 20 in any of
the canine cell lines.
We next examined DNA isolated from seven dogs
diagnosed with ALL. A wild-type 500 bp amplicon was
produced when examining DNA isolated from a healthy
dog and five dogs diagnosed with ALL (Figure 1, lanes
5, 6 and data not shown), and this was confirmed by
DNA sequencing in each case. In contrast, FLT3 ITDs
of differing sizes were found in two other dogs diag-
nosed with ALL (Figure 1, lanes 8, 9). In total, FLT3
ITDs were found in 2/7 (28.5%) dogs diagnosed with
ALL. In contrast to the GL-1 ITD, which produced only
one > 500 bp amplicon, the wild-type FLT3 allele was
also seen in these canine ALL blood samples, either
indicating heterozygosity or contamination with non-
leukemic cells. Similar to the cell line analysis, no point
mutations were found in exons 14/15 or exon 20 in any
of the seven cases.
The predicted amino acid sequence of the ITDs is
shown in Figure 2, based on our DNA sequence data.
The GL-1 ITD is an in-frame 21 bp duplication, while
the clinical cases contain in-frame 47 bp and 87 bp
duplications, respectively. All maintain the same open
reading frame as the original FLT3 sequence. Interven-
ing bases between the repeats that maintain the reading
frame in Cases 1 and 2 cause the insertion of an extra
one to two bases between duplications (Figure 2). Case
2 has an additional point mutation resulting in a V to E
change in the duplicated repeat (Figure 2).
Figure 1 FLT3 PCR of genomic DNA. FLT3 PCR with intronic
primers bracketing exons 14 and 15 was performed and the
products separated on an agarose gel. Samples containing a FLT3
ITD (GL-1, Case 1, and Case 2) have a band with decreased mobility
compared to the wild-type FLT3 gene (500 bp in size), which is
seen in 17-71, CLGL-90, a dog without ALL, and a representative
dog with ALL without the FLT3 ITD.
Figure 2 FLT3 ITD mutations in exon 14 . The amino acid
sequences of the three FLT3 ITD mutations are shown, with the
duplicated region shown below the wild-type sequence of exon 14
for each case. The bolded amino acid(s) are not part of the wild-
type sequence and exist between the two repeats (not duplicated).
The underlined residue in Case 2 is mutated in the duplication only;
the other copy is wild-type. Each of the three ITD mutations are in-
frame.
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Overexpression of FLT3 in samples with a FLT3 ITD
mutation
To begin to define the functional consequences of FLT3
mutations, we compared FLT3 mRNA expression
between samples with and without ITDs. Figure 3 shows
qRT-PCR results for the three canine lymphoid cell
lines, normal canine peripheral blood, and canine ALL
cases with and without FLT3 ITDs. GL-1 FLT3 mRNA
expression was up-regulated relative to other lymphoid
cell lines by more than 30-fold. Likewise, the two clini-
cal ALL cases with a FLT3 ITD mutation had more
than 30-fold increased expression relative to the ALL
case without a FLT3 ITD mutation.
Canine FLT3 ITD mutations are associated with
lestaurtinib sensitivity
The FLT3 ITD results in sensitivity to FLT3 inhibition in
human cells in vitro. We determined whether the GL-1
cell line, containing the FLT3 ITD, is sensitive to the
FLT3 tyrosine kinase inhibitor, lestaurtinib (Figure 4).
A dose dependent growth inhibition of the GL-1 cells
was clearly evident, with an approximately 40% growth
reduction after being exposed to 10 nM lestaurtinib for
96 hrs. This was similar to the response of MV4-11, a
human leukemia cell line with a FLT3 ITD mutation and
documented sensitivity to lestaurtinib [29,30]. In con-
trast, the 17-71 cell line was essentially resistant to the
growth inhibitory effects of lestaurtinib, while the CLGL-
90 cell line showed only a modest reduction in growth.
The culture conditions required to keep primary canine
lymphoma and leukemia cells alive for relevant in vitro
studies are not currently known, therefore, the growth
inhibitory effect of lestaurtinib on neoplastic cells isolated
from the canine ALL patients was not examined.
Canine FLT3 ITD mutation activates the same downstream
mediators as in humans
Finally, in an effort to determine if the downstream
effectors of FLT3 inhibition are similar between the
canine and human cell lines, we examined the expres-
sion and activation of FLT3 and members of the JAK/
STAT and MAP kinase pathways with and without
exposure to lestaurtinib (Figure 5). Upon FLT3 phos-
phorylation and dimerization, both downstream
Figure 3 Expression of FLT3 mRNA. Samples were analyzed by quantitative PCR (Q-PCR) of FLT3. Expression levels relative to CLGL-90, which is
normalized to zero, are shown in log2 units.
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secondary mediators STAT5 and ERK1/2 are activated
via phosphorylation of key residues, which leads to tran-
sit into the nucleus and increased transcription of a
variety of genes involved in cell survival and differentia-
tion. Furthermore, it has been reported that STAT5
activation is a specific effect of the FLT3 ITD, as
opposed to other mechanisms of FLT3 up-regulation
[31-33]. The canine cell line 17-71 expresses little to no
phospho-STAT and phospho-ERK1/2, therefore, no
effect of lestaurtinib on this cell line was seen using this
assay. The CLGL-90 cell line, on the other hand,
expressed a detectable amount of both STAT and
ERK1/2. Growth in lestaurtinib had no effect on the
phosphorylation status of these two proteins. In con-
trast, both the human MV4-11 and canine GL-1 cell
lines showed a decrease in the phosphorylation of FLT3
(although the phospho-FLT3 antibody did not detect
canine FLT3 as strongly as human FLT3), STAT5, and
ERK1/2 when cultured in the presence of lestaurtinib.
In addition, the level of phosphorylated STAT5 was
undetectable after exposure to lestaurtinib, while the
level of phosphorylated ERK1/2 was decreased in both
cell lines.
Discussion
We have demonstrated that both canine and human
leukemias share FLT3 ITD mutations, in agreement
with a previous report [19]. In addition, we show that a
canine B-cell ALL cell line, GL-1, demonstrates amplifi-
cation of the FLT3 ITD allele and loss of the wild-type
FLT3 allele. Also, this is the first report of FLT3 overex-
pression in canine ALL clinical samples. Importantly, we
also document the conserved functional consequences
of the FLT3 ITD mutation. This includes constitutively
activated FLT3, leading to increased phosphorylation of
downstream mediators, and subsequent sensitivity to the
FLT3 inhibitor, lestaurtinib.
Our previous high-resolution aCGH results showing
amplification of the FLT3 locus in canine GL-1 cells led
us to characterize this gene in more detail. Indeed,
FLT3 expression in the GL-1 line is massively up-
regulated, and the GL-1 cell line contains the FLT3 ITD
while lacking wild-type FLT3 (Figure 1). In human
AML, copy-neutral loss of wild-type FLT3, also referred
to as acquired segmental uniparental disomy (aUPD), is
associated with high-risk disease [34]. In a previous sur-
vey of canine leukemias, a heterozygous FLT3 ITD was
found in 3/36 (~8.3%) dogs diagnosed with ALL [19].
Similar to our results, LOH of dog chromosome 25 q
was not seen in this small number of clinical leukemia
samples, therefore, loss of wild-type FLT3 is not com-
mon in clinical specimens. Although the GL-1 cell line
does have 25 q LOH, the normal karyotype reported
when this line was originally published cannot distin-
guish whether loss of the wild-type allele and/or amplifi-
cation of the FLT3 ITD was present initially or
developed with continued in vitro propagation. Regard-
less, the resulting genotype leads to extensive up-regula-
tion of FLT3 in the GL-1 cell line.
Our results differ from human leukemia in that we
observed the FLT3 ITD mutation not infrequently in
ALL (2/7 samples), whereas in humans, the FLT3 ITD
mutation is only rarely seen in ALL (~1% of ALLs) and
is much more common in AML (25% of adult cases;
15% of pediatric cases) [1,2,13-15]. AML is exceedingly
rare in dogs, while ALL is much more common. In
canine patients, both diseases are characterized by an
extremely aggressive biology with overall short survival
times (weeks) when treated with standard multi-agent
chemotherapy. Although FLT3 ITDs are uncommon in
human ALL, FLT3 overexpression has been implicated
Figure 4 Growth inhibition of FLT3 ITD-containing cell lines by
lestaurtinib. Cells were grown in 5 or 10 nM lestaurtinib. Viability
of each cell line is shown relative to its growth in media without
lestaurtinib. Experiments were done in triplicate, and standard error
of the mean is shown.
Figure 5 Downstream mediators of FLT3 ITD. Protein levels of
FLT3, phospho-FLT3, phospho-STAT5 and phospho-ERK were
assayed by Western blotting. Protein was harvested from cell lines
that were grown both with and without lestaurtinib. Beta-actin was
used as a loading control.
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in the pathogenesis of infant and childhood ALL [16].
Our results showing that FLT3 mutations lead to over-
expression and/or activation of FLT3 in both the GL-1
cell line and clinical canine ALL cases is similar to find-
ings examining human ALL cell lines and infant/child-
hood ALL, although the mechanism of activation more
resembles that in human AML (i.e. ITD mutation).
In conjunction with others reports, our results show
that, similar to human AML, canine ALL samples also
contain differing lengths of ITDs. Also, the canine ITDs
maintain the reading frame of the FLT3 protein. These
similarities suggest that the mechanism of mutation is
conserved across species. Data from human patients
suggest that a longer ITD mutation is associated with
lower CR rates and worse survivals [35,36]. Confirma-
tion in dogs awaits larger numbers and improved treat-
ments to increase overall survival times to a point where
cross-species comparisons are possible.
FLT3 plays an important developmental role and is
overexpressed in most patients with AML, therefore, it
is an attractive target for the development of selective
small molecule inhibitors. Lestaurtinib, a FLT3 inhibitor,
selectively kills human ALL cell lines and primary child-
hood ALL cells that express high levels of FLT3. It is
also more toxic to AML cell lines with a FLT3 ITD than
those without it [29,30]. Our findings demonstrate that
the canine GL-1 cell line, which exhibits high-level
FLT3 expression and the FLT3 ITD mutation, is also
sensitive to low concentrations of lestaurtinib. This
result mirrors the effects of lestaurtinib on the human
leukemia cell line MV4-11, which, like GL-1, contains a
FLT3 ITD mutation with high expression levels [29,30].
In addition, we confirmed that the inhibition of prolif-
eration of the GL-1 cell line by lestaurtinib is most likely
mediated via decreased levels of the STAT5 and ERK1/2
phosphoproteins, all of which reinforces the underlying
conservation between dysregulated pathways in humans
and canine leukemia, even across diseases (AML and
ALL, respectively).
Conclusions
In summary, we present data that shows ALL/FLT3
biology is conserved across human and canine species.
Canine ALL patients, in addition to the canine B-cell
leukemia cell line, GL-1, contain FLT3 mutations that
lead to FLT3 up-regulation and subsequent activation of
members of the JAK/STAT and MAP kinase pathways.
In particular, the GL-1 cell line, which has massively
up-regulated FLT3 expression as well as a typical FLT3
ITD mutation, will serve as a sensitive tool to test FLT3
selective inhibitors. Thus, this data will lay the ground-
work for future studies of leukemogenesis, supporting
the notion that canine ALL can be viewed as a relevant
large animal model for human FLT3 ITD-positive
leukemias and is useful for the development of novel
therapeutics and/or treatment strategies for both dogs
and humans.
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